We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M Turnover 22.92%
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+19.23%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$140M
AUM Growth
+$21.9M
Cap. Flow
+$4.55M
Cap. Flow %
3.25%
Top 10 Hldgs %
48%
Holding
83
New
9
Increased
22
Reduced
16
Closed
8
Avg Time Held
1.4 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$2.79M
2
IMMU
Immunomedics Inc
IMMU
+$2.7M
3
DERM icon
Dermira, Inc.
DERM
+$1.44M
4
SGMO icon
SANGAMO THERAPEUTICS INC
SGMO
+$1.44M
5
NERV icon
Minerva Neurosciences
NERV
+$1.42M

Top Sells

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$2.61M
2
TVRD icon
Tvardi Therapeutics
TVRD
+$1.75M
3
NVDQ icon
Novadaq Technologies Inc.
NVDQ
+$747K
4
MTVA icon
MetaVia Inc
MTVA
+$725K
5
ABEO icon
Abeona Therapeutics
ABEO
+$338K

Sector Composition

Rank Sector Weight
1 Healthcare 92.55%
2 Miscellaneous 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TMBR
76
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-8
Closed -$58K –
NVDQ icon
77
DELISTED
Novadaq Technologies Inc.
NVDQ
– –
-95,841
Closed -$747K –
1 2 3
4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, DAFNA Capital Management held 83 positions worth $140M, up 19% from $118M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $4.55M of net new capital in Q2 2017, opening 9 new positions and adding to 22 existing holdings. Its largest new stake was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AtriCure, an estimated $2.61M trimmed.

  • DAFNA Capital Management's largest Q2 2017 buy was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.
  • DAFNA Capital Management added most to Aerie Pharmaceuticals in Q2 2017, an estimated $2.79M increase.
  • DAFNA Capital Management's biggest Q2 2017 reduction was AtriCure, cutting an estimated $2.61M.
  • DAFNA Capital Management fully exited Tvardi Therapeutics in Q2 2017, selling an estimated $1.75M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $140M portfolio in Q2 2017.
  • DAFNA Capital Management opened 9 new positions and closed 8 in Q2 2017.
  • DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $140M.

Based on DAFNA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.